Comparative Pharmacology
Head-to-head clinical analysis: ETHRANE versus ETOMIDATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ETHRANE versus ETOMIDATE.
ETHRANE vs ETOMIDATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Enflurane is a volatile inhalational anesthetic that potentiates GABA-A receptor activity and inhibits excitatory neurotransmission, resulting in general anesthesia.
Etomidate is a nonbarbiturate hypnotic agent that acts as a positive allosteric modulator of the gamma-aminobutyric acid (GABA) type A receptor, enhancing GABA-mediated inhibition in the central nervous system. It produces rapid anesthesia with minimal cardiovascular and respiratory depression.
1-5% inspired concentration via inhalation, titrated to effect for maintenance of general anesthesia.
Induction: 0.2–0.6 mg/kg IV over 30–60 seconds. Maintenance: 10–20 mcg/kg/min IV continuous infusion.
None Documented
None Documented
Clinical Note
moderateEtomidate + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Etomidate is combined with Fluticasone propionate."
Clinical Note
moderateEtomidate + Clemastine
"The risk or severity of adverse effects can be increased when Etomidate is combined with Clemastine."
Clinical Note
moderateEtomidate + Venlafaxine
"Etomidate may decrease the antihypertensive activities of Venlafaxine."
Clinical Note
moderateEtomidate + Nefazodone
Context-sensitive half-life: approximately 2-5 minutes after short procedures; prolonged after prolonged administration due to slow washout from fat stores.
Terminal elimination half-life: 2.9–5.3 hours (context: redistribution shortens clinical effect; hepatic impairment prolongs).
Primarily exhaled unchanged via lungs (>95%); less than 5% metabolized in liver to fluoride ion and other metabolites, with renal excretion of metabolites.
Renal: 75% as metabolite (carboxylic acid), 2% unchanged; fecal/biliary: minimal.
Category C
Category C
General Anesthetic
General Anesthetic
"The risk or severity of adverse effects can be increased when Etomidate is combined with Nefazodone."